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TO THE EDITOR
Revertant mosaicism refers to the pre-
sence of two genetically heterogeneous
populations of cells as a result of
spontaneous genetic correction during
mitosis (Hall, 1988; Jonkman et al.,
1997). This phenomenon has been
reported in several inherited diseases,
including severe combined immunode-
ficiency, Bloom’s syndrome, Fanconi’s
anemia, X-linked Wiscott–Aldrich syn-
drome, Duchenne muscular dystrophy,
and tyrosinemia type I (Hirschhorn,
2003). With regard to genodermatoses,
cutaneous revertant mosaicism has
been described in epidermolysis bull-
osa (EB) (Fine et al., 2008). Notably,
in vivo reversion of mutations in
LAMB3, COL17A1, and KRT14 has
underscored cutaneous mosaicism in
non-Herlitz junctional EB and EB sim-
plex, respectively (Darling et al., 1999;
Schuilenga-Hut et al., 2002; Smith
et al., 2004; Pasmooij et al., 2005,
2007; Jonkman and Pasmooij, 2009).
Of potential clinical interest, such
genetic events may not be that rare—
perhaps occurring in up to one-third of
cases of non-Herlitz junctional EB
(Jonkman and Pasmooij, 2009). Multi-
ple corrective mechanisms have been
proposed or observed, including back
mutations, intragenic crossovers, mito-
tic gene conversions, and second-site
mutations (Jonkman et al., 1997;
Pasmooij et al., 2005; Frank and
Happle, 2007). Indeed, several different
corrective processes can occur in the
same patient (Jonkman and Pasmooij,
2009). The implications for phenotype,
however, depend on several factors,
including the timing and extent of the
revertant mosaicism. Here we report a
further example of revertant mosaicism
in a different sub-type of EB, with
probable intragenic crossover in the
COL7A1 gene leading to restoration of
basement membrane collagen VII and
anchoring fibrils in a patch of skin
in an individual with recessive dys-
trophic EB.
The proband is a 41-year-old Cau-
casian British man with severe general-
ized recessive dystrophic EB (Fine et al.,
2008). He has mutilating scars with
bilateral mitten deformities and a his-
tory of recurrent squamous cell carci-
nomas. His skin is prone to trauma-
induced blistering, although for as long
as he can remember, two small patches
of skin on his left wrist and right
shin never seem to blister despite
repeated trauma. Examination of these
sites revealed areas approximately
85 cm2 that resembled the normal
skin in appearance and texture
(Figure 1a and b). To explain the
phenotypic heterogeneity, and follow-
ing ethics committee approval (St
Thomas’ Hospital Ethics Committee:
07/H0802/104) and informed consent
and in accordance with the Declaration
of Helsinki principles, skin from the left
wrist was investigated with biopsy
specimens taken from both the
blister-prone area (unreverted) and the
normal-appearing skin (reverted). Im-
munolabeling for collagen VII (clone
LH 7.2; Sigma-Aldrich, Poole, UK) and
transmission electron microscopy
were performed as described else-
where (McGrath et al., 1993) and the
results are illustrated in Figure 1c–e.
Sequencing of peripheral leukocyte
genomic DNA revealed that the
patient is a compound heterozygote
for two loss-of-function mutations in
COL7A1, c.1732C4T (p.Arg578X) in
exon 13 (maternal) and c.7786delG
(p.Gly2593fsX4) in exon 104 (paternal)
(Figure 2a). Both of these are recurrent
mutations within the white British
population (Mellerio et al., 1997).
To explain the heterogeneous skin
phenotype, genomic DNA and RNA
were extracted from whole skin from
both unreverted and reverted areas
using standard kits (DNA Extraction
Minikit and RNAEasy Minikit, Qiagen,
Crawley, UK), as well as from cultured
fibroblasts from both sites (TRIzol,
Invitrogen, Paisley, UK) using the man-
ufacturer’s protocols. The fibroblast
cultures were performed using standard
methods (Wong et al., 2008). cDNA
was generated using commercial kits
and protocols (IScript cDNA generation
kit, Biorad, Hemel Hempstead, UK).
Reverse transcriptase-PCR was per-
formed across the sites of both muta-
tions and the results are illustrated in
Figure 2b. Real-time reverse transcrip-
tase-PCR was also carried out to assess
COL7A1 gene expression in the differ-
ent skin and cell samples with primers
(details available on request) specifi-
cally designed to amplify a 200-bp
region of the COL7A1 30UTR (Syber-
Green Master Mix, Applied Biosystems,
Warrington, UK). Reverse transcriptase-
PCR for each cDNA sample was carried
out in triplicate and the results are
illustrated in Figure 2c. Collectively,
these investigations indicated that the
reverted skin expressed collagen VII
and that anchoring fibrils were present.
In addition, the reverse transcriptase-
PCR data demonstrated that there was
expression of wild-type cDNA spanning
the frameshift mutation in exon 104 and
that COL7A1 gene expression levels
were similar to those seen in the
patient’s brother who was heterozygous
for one mutant COL7A1 allele (Figure
2c). Moreover, the gene correction in
the patient’s reverted skin appeared to
have occurred in keratinocytes rather
than fibroblasts. To explore the me-
chanism of this correction, we per-
formed long-range sequencing of the
patient’s reverted skin cDNA using
LongAmp Taq DNA polymerase (New
England Biolabs, Hitchin, UK). We first
searched for polymorphisms to distin-
guish between maternal and paternal
alleles and identified differences for a
common PvuII polymorphism in exon
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21 (c.2817G/A; rs1264194). Although
no other potentially informative intra-
genic polymorphisms were detected,
sequencing was able to demonstrate a
COL7A1 allele bearing neither muta-
tion (in exon 13/104) in combination
with a paternally derived A nucleotide
for the exon 21 polymorphism. These
data are consistent with intragenic
crossover occurring somewhere be-
tween exons 21 and 104 (Figure 2d).
The net result is the generation of a patch
of skin that functions similarly to that
seen in a heterozygous carrier for one
loss-of-function mutation in COL7A1.
The area of potential revertant
mosaicism on the patient’s right shin
was not investigated in this study.
Identification of a patch of revertant
mosaicism that shows functional prop-
erties similar to those of a heterozygous
carrier now provides new therapeutic
opportunities for patients. Expansion of
revertant keratinocytes in non-Herlitz
Normal control
*
Figure 1. Clinicopathological assessment identifies patches of revertant mosaicism showing collagen VII expression and anchoring fibrils at the DEJ.
(a) Patch of skin on the left wrist and (b) right shin that show no signs of skin blistering. (c) Skin biopsy of the patient’s unreverted skin that reveals a complete
absence of collagen VII at the DEJ (arrows depict DEJ, asterisk indicates a blister) and ultrastructurally there is a lack of anchoring fibrils and early blister
formation beneath the lamina densa. (d) In contrast, in the reverted skin there is bright linear labeling of collagen VII at the DEJ and several anchoring fibrils are
present. (e) Normal control skin showing bright linear collagen VII immunostaining at the DEJ of similar intensity to the patient’s reverted skin. The anchoring
fibrils below the lamina densa in normal control skin are similar to those seen in the patient’s reverted skin, but appear somewhat longer, with more clearly
discernible central cross-banding (for immunofluorescence microscopy images, bar¼ 50mm; for transmission electron microscopy images, bar¼0.1 mm).
DEJ, dermal–epidermal junction.
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junctional EB and grafting onto unre-
verted sites have already been at-
tempted (Gostynski et al, 2009),
although low levels of reversion in the
graft material led to no appreciable
clinical benefit in that case. Never-
theless, this approach represents an
exciting possibility for our patient with
recessive dystrophic EB. In addition,
recent technological advances enabling
creation of inducible pluripotent stem
cells from keratinocytes also offer new
possibilities for translational research
(Aasen et al., 2008). Thus, the ‘‘natural
gene therapy’’ observed in this patient
may hold considerable future therapeu-
tic potential.
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Figure 2. Revertant mosaicism is likely to result from intragenic crossover in COL7A1. (a) Sequencing of genomic DNA (gDNA) from the patient’s unreverted
skin that reveals compound heterozygosity for the mutations c.1732C4T (p.Arg578X) in exon 13 and c.7786delG (p.Gly2593fsX4) in exon 104, as also
delineated in peripheral blood leukocyte genomic DNA (not illustrated). Both mutations are present in genomic DNA from the reverted skin (center panels).
Normal control genomic DNA wild-type sequences are also illustrated. (Genomic DNA sequence traces across the mutation c.7786delG are shown in flipped
reverse orientation for uniformity.) (b) Sequencing of complementary DNA (cDNA) extracted from the patient’s unreverted skin showing the presence of both
loss-of-function mutations. In contrast, in the patient’s reverted skin, the nonsense mutation can still be detected, but across the site of the frameshift mutation in
exon 104, only the wild-type sequence is evident. Normal control cDNA wild-type sequences are also illustrated. (c) Real-time reverse transcriptase-PCR
showing barely detectable COL7A1 gene expression in the patient’s skin or cultured fibroblasts derived from the unreverted area. In contrast, in the reverted skin,
COL7A1 gene expression levels are similar to those seen in the patient’s brother (a heterozygous carrier of one COL7A1 mutation), but cultured fibroblasts from
the reverted area fail to show a similar increase in COL7A1 gene expression to that seen in the brother. (d) The maternal nonsense mutation in exon 13 occurs on
the same allele bearing a G nucleotide for a PvuII polymorphism in exon 21, but in the reverted skin the wild-type sequence for exon 104 occurs on the same
allele bearing a paternal A nucleotide for the exon 21 polymorphism. This suggests that intragenic crossover has occurred somewhere between exons 21 and
104, and that the patient has restored one functional COL7A1 allele that is capable of generating collagen VII protein at the dermal–epidermal junction, as well
as morphologically recognizable anchoring fibrils.
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Langerhans Cell Mobilization Distinguishes between
Early-Onset and Late-Onset Psoriasis
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TO THE EDITOR
Psoriasis is an immune-mediated chronic
inflammatory skin disease that affects
approximately 2% of the population. The
etiology of psoriasis is currently un-
known, but the identification of several
psoriasis susceptibility loci suggests that
genetic disposition has an important role
in its development, with environmental
factors acting as triggers.
There are two distinct ages of onset for
psoriasis. Early onset occurs before the
age of 40 years and accounts for 75% of
cases, whereas late onset presents after
the age of 40 years, with a peak between
55 and 60 years of age. Although the two
types of psoriasis appear to be very
similar clinically, they are genetically
distinct. The HLA-Cw6 allele is asso-
ciated with early-onset, but not with late-
onset psoriasis, although this is not
absolute (Henseler and Christophers,
1985; Allen et al., 2005). Indeed, this
allele is found in approximately 43–54%
of early-onset patients, but in only
17–29% of those with late-onset psor-
iasis, the latter being comparable to the
frequency of 14–20% in the general
population (Mallon et al., 1997; Chang
et al., 2003; Allen et al., 2005).
We have found previously that the
function of epidermal Langerhans cells
(LCs), and specifically LC mobilization
and migration, is profoundly impaired in
the uninvolved skin (PN) of early-onset
psoriasis patients compared with the skin
of healthy volunteers (NN). In normal
subjects, skin sensitization (Griffiths
et al., 2001), or the intradermal injection
of either tumor necrosis factor-alpha
(TNF-a) or interleukin-1 beta (IL-1b;
Cumberbatch et al., 1999, 2003), stimu-
lates the mobilization of LCs and their
migration to draining lymph nodes. In
patients with early-onset psoriasis, LC
migration in response to IL-1b, TNF-a,
and a contact allergen was in all cases
shown to be substantially reduced or
completely absent in the PN (Cumber-
batch et al., 2006).
As LC function appears to have a
key role in the pathogenesis of psoriasis
(Cumberbatch et al., 2006; Werner
et al., 2008), we questioned whether
LC migration in response to either TNF-a
or IL-1b is similarly impaired in the PN of
patients with late-onset psoriasis. In all,
10 patients with late-onset psoriasis
(mean age 59.9±1.6; age of onset
54.7±1.1), 5 healthy volunteers (mean
age 64.5±2.2), and 3 patients with
early-onset psoriasis (mean age 57.3±
3.9) provided written informed consent
for the study, which was approved by the
Salford and Trafford Research Ethics
Committee and was conducted in ac-
cordance with the Declaration of
Helsinki. All study participants were
Caucasian. Inclusion criteria included
no use of systemic therapies for 4 weeks
and no use of topical therapies for 2
weeks before participation in the study.
Subjects received one intradermal injec-
tion of saline in the clinically uninvolved
(PN) buttock or hip skin, at a position
Abbreviations: IL-1b, interleukin-1 beta; LC, Langerhans cell; NN, skin of healthy volunteers; PN,
uninvolved skin of patients with psoriasis; TNF-a, tumor necrosis factor-alpha
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